PRINEVILLE, Ore., Sept. 15, 2026 — Samson Sky, makers of the Switchblade Flying Car announced they have secured an investment of $80 million from Dubai-based Matin Group. According to Sam Bousfield, CEO and Founder of Samson Sky and designer of the Switchblade, these funds will be used to establish Samson Sky’s first 180,000 square foot Switchblade production facility, to be located in the U.S.

Samson Sky announced they have signed a Joint Investment Agreement with the Matin Group, and the two companies have begun setting up the Joint Venture to accelerate into commercial production, with $20M still remaining to be raised for full production funding.

The transaction reflects Matin Group’s strategy of selectively partnering with innovative, execution-ready businesses that combine strong commercial potential with long-term value creation. Former aerobatic pilot and Samson Sky Ambassador Anna V. Grebenshchikova was instrumental in bringing the two organizations together.

“At the start, Mr. Matin saw the Switchblade’s relevance, and its ability to make a difference in the world, and our two companies quickly advanced to a position of trust,” said Bousfield. “We are proud to have such a forward-thinking partner as we roll the Switchblade out to the world.”

“The future is not built by those who wait for certainty—it is built by those who recognize possibility before it becomes obvious. At Matin Group, we partner with people who have the courage to challenge convention and the discipline to deliver. Samson Sky is one of those rare companies, and we are proud to support their journey as they redefine the future of mobility, because we believe the most meaningful investments are those that create lasting value—not only for shareholders, but for society as a whole,” stated Mustafa Matin, CEO of Matin Group.

With seating for two plus luggage, the Switchblade Flying Car is a hybrid-electric driving and flying vehicle with sports car performance on the ground and high performance in the air. It runs on premium auto gas, fits in a standard garage and is driven to a nearby airport using highways or local roads.

Matin Group is a privately held, family-led investment and strategic holding group headquartered in Dubai, United Arab Emirates, with origins in London. Through its Finance and  Investment division, the Group specializes in structured project financing, investment structuring, and selective equity participation, partnering with experienced operators, institutions, and project sponsors across multiple sectors.

Guided by disciplined capital allocation and long-term value creation, Matin Group invests in opportunities where strategic partnership, sound governance, and execution excellence create enduring commercial value. The Group maintains an international outlook with activities spanning the Middle East, Europe, Central Asia, Africa, and North America. 

Samson Motors, Inc. (dba Samson Sky) has been dedicated in designing, building, and testing the industry-leading Switchblade Flying Car as a high-performance vehicle that both drives and flies, to solve the problems of Regional Travel (200-500 miles). For safety and insurability, all flying surfaces are enclosed within the vehicle while in driving mode. The Switchblade transforms from driving to flying mode in three minutes at the push of a button. The Switchblade Flying Car had its successful official First Flight in Nov. 2023. Samson Sky is now bringing that world-class vehicle into production to satisfy the demand from 50 countries world-wide and from each of the 50 States in the U.S.  

For more information about the Switchblade and to follow its progress into production, visit: www.SamsonSky.com

Media Contact:

Gail Gallegos 916-769-6979 (Mobile)
[email protected] 
Additional Hi-Res images available by request

PLEASE NOTE:
The Switchblade is an Experimental category aircraft. The U.S. Federal Aviation Administration (FAA) does not provide Certification for this category of aircraft – they certify aircraft that are fully produced in a factory by the manufacturer.

With all Experimental aircraft, the FAA designates that the owner must build 51% of the vehicle. All Switchblade owners will spend one week at the Samson Builder Assist Center, building 51% of their Switchblade. Following this, Samson will complete their vehicle.

SOURCE Samson Sky

Therna’s novel proprietary method generates millions of functional RNA measurements within a dynamic biological system, producing unique data sets from single experiments. A representative data set is now available to researchers and prospective partners.

SAN FRANCISCO, Sept. 15, 2026 — Therna Biosciences, a biotechnology company whose AI RNA Biologist, RNA-Logix™, translates RNA language into medicines, today announced the launch of Chronos and the public release of one representative Chronos study set. Chronos is the novel data engine of RNA-Logix™, generating orders of magnitude more functional RNA data than the industry standard in a single experiment, representing the complexity of a whole biological system.

Chronos is a highly multiplexed measurement of expression dynamics for tens of thousands of synthetic genes and mRNAs across dozens of diverse human cell lines, resulting in millions of functional RNA measurements in every single experiment. Researchers and prospective partners can use the released study sets to train and benchmark sequence-to-function models, test how the same RNA sequence behaves across different cellular contexts and over time, and evaluate design rules for expression, stability, and cell-type-specific behavior.

“All biological models, including RNA design models, are defined by the quality and scale of the biological data behind their design and whether it represents the complexity of the biological system,” said Nazli Azimi, Ph.D., Chief Executive Officer of Therna. “Therna is built on the belief that RNA is a language, and that a company able to understand it can write medicines in it. RNA-Logix™ is Therna’s AI RNA Biologist, unlocking new biology and designing the novel medicines that act on it. All of that begins with data. Chronos fundamentally changed how we generate that data at a scale and the complexity that interrogates RNA dynamics within a living system. We are releasing one data set to show the field what becomes reachable when scale and dynamic measurements are taken into account.”

Conventional methods measure one mRNA, in one cell type, at one moment. Chronos measures tens of thousands of synthetic mRNAs across a pool of 50 human cell lines and follows them over time, all within a single experiment, at a scale that would otherwise take months of separate experiments to assemble. Analyzing millions of single cells requires a matching computational approach. Therna achieved an approximately 200x speedup using rapids-single cell, an open-source scverse package built on NVIDIA CUDA-X for Data Science.

“For years we could ask what one RNA does in one cell type and get a clean answer to a narrow question. Chronos lets us ask what thousands of sequences do across 50 cellular contexts at once, and the answer is not the same in every cell,” said Hani Goodarzi, Ph.D., Scientific Co-Founder of Therna, Core Investigator at the Arc Institute, and faculty at the University of California, San Francisco. “That variation is the point. It tells us how a sequence and the cell reading it combine to set behavior, which is what a model of the cell needs to learn and has not had. It also turns that biology into design: which part of an RNA to target to drive a therapeutic response, and what to put into an mRNA so it works hardest in the cell type we are aiming at.”

Therna is releasing the Chronos data set conducted on 50 human cell lines (courtesy of Tahoe Therapeutics). The release comprises one study set generated on Chronos: Penta-47x27K and Tria-47x28K which are available on Hugging Face, along with a technical white paper covering the data set, quality control, and preliminary sequence-to-function modeling. In collaboration with Lightning AI, Therna is also releasing a Lightning Studio so users can interact with the data directly. The release does not include experimental protocols or Therna’s RNA foundation models. A separate Chronos study set generated in human immune cells remains proprietary, supporting the Company’s internal programs and partnered work.

Therna is making these study sets available so prospective partners and the broader community can see the scale and complexity of the data that RNA-Logix™ is built and trained on. The Company invites researchers to train on the study sets, benchmark against them, and publish their findings, and welcomes contact from organizations that see an application to their own biology.

Organizations interested in applying Therna’s proprietary human immune cell Chronos study set to their own biology are invited to contact Therna about collaboration.

About Therna Biosciences

Therna is a biotechnology company translating RNA language into medicines. Its platform, RNA-Logix™, is an AI RNA Biologist that unlocks new biology and designs the novel medicines that act on it. Because RNA-Logix™ treats mRNA both as a medicine and as a target, Therna designs across modalities on one platform, engineering mRNA optimized for translation, stability, immune evasion, and tissue-specific expression, and identifying optimal target sites within mRNA for ASO and siRNA design. Therna’s technology can increase, decrease, or finely tune gene expression, enabling applications across cardiovascular, metabolic, immunological, and genetic diseases, in addition to ultra-rare, individualized treatments. Headquartered in San Francisco, Therna is backed by leading investors and scientific advisors at the forefront of RNA and AI innovation. Please visit therna.com for more information.

SOURCE Therna Biosciences

Investment will accelerate Radian Forge’s advanced manufacturing capacity for U.S. naval, maritime and defense applications.

MCLEAN, Va., Sept. 15, 2026 — Veteran Ventures Capital (VVC) today announced that it has led the $2.5 million Series Seed Preferred financing in Radian Forge, a Virginia-based advanced manufacturing company building on-demand production capacity for the U.S. maritime and defense industrial base.

The financing was made through VVC’s Fund II, with additional participation from the Virginia Innovation Partnership Corporation (VIPC) and Radian Forge’s existing investors.

Headquartered in Portsmouth, Virginia, adjacent to some of the nation’s largest naval shipbuilding and repair facilities, Radian Forge produces large-scale, precision-grade metal components for naval, maritime and defense applications using large-format Wire Arc Additive Manufacturing (WAAM). The process produces large, complex components with material properties between castings and forgings, while reducing production lead times by 40–80% and enabling each WAAM robot to operate with a single operator.

“The United States cannot sustain naval power or rebuild its fleets without a responsive manufacturing base capable of producing critical components at the speed of the mission,” said Joshua Weed, General Partner at Veteran Ventures Capital, who led the investment and will join Radian Forge’s Board of Directors. “Radian Forge is building the domestic manufacturing capacity needed to help close that gap.”

The investment comes as the United States works to rapidly expand shipbuilding and repair capacity, strengthen domestic supply chains and address production constraints across the maritime industrial base.

“America has spent decades accepting manufacturing timelines that no longer match the urgency of the mission. We don’t accept them. Radian Forge is building the capacity to put critical components into the hands of our customers in weeks, not months. This investment allows us to move faster and scale that capability. Veteran Ventures understands that this isn’t just a manufacturing problem—it’s a readiness problem—and that’s exactly the kind of partner we want beside us,” said Jeff Yeager, CEO of Radian Forge and former U.S. Marine.

In February 2026, Governor Abigail Spanberger announced that Radian Forge would invest $10.5 million to expand its Portsmouth operations, creating 53 new jobs, with the Commonwealth approving a $265,000 Opportunity Fund grant. VIPC’s latest direct equity investment expands and strengthens the Commonwealth’s commitment.

About Veteran Ventures Capital

Veteran Ventures Capital invests in dual-use national security technologies, focusing on companies led by veteran entrepreneurs and operators. Committed to advancing U.S. technological superiority, Veteran Ventures Capital provides capital, mentorship, and strategic guidance to high-growth companies serving critical government and commercial markets. VVC’s portfolio includes leading companies in defense, aerospace, advanced manufacturing, cybersecurity, and other sectors essential to national security, including notable investments in Vatn Systems, Hidden Level, Cambium, Agile Space Industries, Turion Space, Hybron Technologies, and Asylon Robotics, amongst others. For more information, visit www.veteranventures.us and follow the firm on LinkedIn.

About Radian Forge

Radian Forge restores speed, scale, and resilience to U.S. defense manufacturing. The company produces large-scale, precision-grade metal components for naval, maritime, and defense applications using large-format Wire Arc Additive Manufacturing, enabling faster production, reduced lead times, and a stronger maritime industrial base. Founded and led by Jeff Yeager, a service-disabled U.S. Marine Corps veteran, Radian Forge is built by those who understand the mission and the manufacturing systems that support it. For more information, visit radianforge.com.

Media Contact

For media inquiries, please contact: [email protected]

SOURCE Veteran Ventures Capital

Open-1b lets anyone independently verify how it was trained, setting a new standard for transparency and accountability for future AI systems.

LONDON, Sept. 15, 2026 — Gensyn, the industry’s leading decentralized AI lab, announced the launch of open-1b, a verifiable AI model designed to allow anyone to test and independently verify how it was trained.

As AI plays a growing role in human life, influencing personal and business decisions, transparency into its development remains closed off. Users have little insight into how these systems are built, trained, or shaped by data. Meanwhile, leaders from the world’s largest AI companies continue to warn about the risks of the technology’s rapid advancement.

Ben Fielding, Co-Founder and CEO of Gensyn, explained, “Auditable AI means a model’s decisions do not have to come from a black box like Anthropic or OpenAI models. Today, Gensyn has unveiled the toolkit that allows someone to inspect the data that shaped it, verify the training process step by step, and understand why it reached a particular conclusion. To achieve our goals with Gensyn, we need AI models that anyone can trust and verify themselves without relying on a company’s version of the truth. Open-1b is a tremendous milestone for the AI industry, proving a path toward verifiable AI, an absolute necessity for the future of intelligence.”

How open-1b compares to existing AI models:

• Closed AI models (e.g., Claude, ChatGPT): Provide access to model outputs, while keeping training methodologies entirely proprietary.
• Open-weight models (e.g., Llama): Distribute model weights, but omit the underlying training process.
• Open-recipe models (e.g., OLMo): Offer both the model weights and the instructions used for training.
• Auditable AI (Gensyn’s open-1b): Delivers the model, the training recipe, and verifiable proof allowing third parties to independently audit any stage of training.

Simply sharing an AI model’s code and datasets is insufficient for true independent verification, as hardware variations frequently lead to inconsistent results. Gensyn addresses this fundamental challenge by providing infrastructure that ensures training outcomes can be accurately reproduced and verified across diverse hardware. Demonstrating this capability, open-1b lays the groundwork for fully auditable artificial intelligence.

Gensyn is moving AI transparency beyond disclosure to proof, giving people the tools to verify how a model was trained for themselves.

About Gensyn
Gensyn is a decentralized AI lab building forecasting systems that continuously improve by learning from real-world outcomes. Its technology combines verifiable AI infrastructure, which allows predictions to be checked against independently verified outcomes, with incentives for people to contribute new information that models have not previously seen. Together, these capabilities create a continuous cycle of prediction, verification, and learning.

Gensyn is backed by a16z crypto, CoinFund, Galaxy Digital, Eden Block, Maven 11, and more. For more information, visit gensyn.ai.

Media Contact
Michelle O’Connor
‪(415) 578-0156
[email protected]

SOURCE Gensyn

• Company’s Cognitive Network Restoration Therapy (CNRT) technology aims to make meaningful cognitive recovery possible years after initial injury
• Targeting a brain hub involved in executive function, CNRT activates underperforming networks to reverse deficits and restore independence
• Groundbreaking therapeutic approach has the potential to transform chronic cognitive impairment care from rehabilitation to restoration

EDINA, Minn., Sept. 15, 2026 — ReEmerge, Inc. (ReEmerge), a private MedTech company innovating a new way to address cognitive impairment, launched from stealth today following the close of an oversubscribed $37M Series A financing. The proceeds will support an upcoming clinical study that will evaluate ReEmerge’s proprietary Cognitive Network Restoration Therapy (CNRT) in its first clinical indication, traumatic brain injury (TBI), while advancing technology development, expanding clinical and regulatory operations, and preparing the platform for future indications. U.S. Venture Partners (USVP) and Santé co-led the round, with significant participation from Oxford Science Enterprises, 415 Capital, IAG Capital Partners, The Vertical Group, and Dendrion Ventures.

“ReEmerge’s technology represents a fundamentally different approach to cognitive recovery with the potential to transform the recovery pathway,” commented Jonathan Root, MD, General Partner at USVP. “The size of the opportunity and the profound unmet need make this an especially compelling market for innovation. We are excited about this technology and the new hope it aims to offer patients and their families.”

“TBI does not discriminate. It can happen to anyone at any age, and its consequences can fundamentally alter a person’s ability to live, work, and engage with the world around them,” said Auriel August, MD, Principal at Santé. “CNRT could offer people living with TBI something they have too often been told not to expect, namely the possibility of meaningful cognitive recovery.”

CNRT is a proprietary, first-of-its-kind approach that precisely targets neural networks in the central thalamus, a brain hub involved in attention, arousal, and executive function.  Rather than bypassing damaged pathways or asking patients to compensate for lost function, CNRT aims to augment the recovery journey by driving underactive but viable neural circuits. By restoring function across existing but underperforming networks, CNRT aims to reverse cognitive deficits and allow recovery to extend further.

This technology grew out of decades of research by Nicholas Schiff, M.D. Professor of Neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine and colleagues at Stanford University and the University of Utah, which explored the possible restorative effect of brain electrical stimulation after TBI. A pilot study showed promising results, with patients regaining cognitive function. The Center for Technology Licensing at Weill Cornell worked closely with Dr. Schiff’s team to protect the intellectual property, provide internal translational gap funding, and license the foundational intellectual property to ReEmerge to advance clinical and commercial development of CNRT.

Building upon this groundbreaking clinical research, including a publication in Nature Medicine, ReEmerge will conduct a prospective, single-arm, multicenter study (NCT07730099) to evaluate this treatment, enrolling up to 40 patients with chronic moderate-to-severe TBI. Additionally, the study will explore potential effects on cognitive and functional outcomes.

“As a physician-scientist and co-founder, it has been very rewarding to see the arc of benchtop science moving forward and being translated into a meaningful clinical development pathway,” stated Dr. Schiff. “I am excited for us to advance the testing of treatment for many patients, who have historically had limited therapeutic options, as we look to shift cognitive care from rehabilitation to restoration and ultimately, to redefine recovery.”

Each year, an estimated 27 million people worldwide experience a traumatic brain injury, and many are left with persistent cognitive impairment.¹ Current recovery pathways focus on rehabilitation, helping patients compensate for cognitive deficits through structured routines, adaptive strategies, and supportive therapies. While these interventions can improve function, the journey can be long, and recovery will often plateau, frequently leaving patients with lasting impairments that limit independence, quality of life, and personhood.

“The strong support of our stellar investor syndicate validates our mission to evolve the recovery trajectory for patients living with impaired cognitive function,” said Todd Langevin, Chief Executive Officer of ReEmerge. “We look forward to initiating our clinical study in TBI and building a robust body of evidence to support our differentiated approach to treating cognitive impairment.”

About ReEmerge, Inc.

ReEmerge is innovating a new way to approach chronic cognitive impairment. Developed under an exclusive licensing agreement with Cornell University, the company’s novel Cognitive Network Restoration Therapy (CNRT) precisely targets neural networks disrupted by brain injury that drive underactive but viable neural circuits. By restoring function across these existing but underperforming networks, CNRT aims to reverse cognitive deficits and restore agency and personhood. To learn more about how the company is developing therapeutic innovations that evolve cognitive care from rehabilitation to restoration, please visit ReEmergeInc.com.

Media Contact
Charlene Herndon
SPRIG Consulting
[email protected]

¹Guan B, Anderson DB, Chen L, et al. Global, regional and national burden of traumatic brain injury and spinal cord injury, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
BMJ Open 2023;13:e075049. doi: 10.1136/bmjopen-2023-075049

For decades, analytics infrastructure has been built for humans. Events are stored flat as rows, columns and precomputed aggregates; any question about the order things happened in has to be reassembled at query time, and the more event types a company keeps, the slower and pricier it gets. Most deployments capture only a few hundred distinct event types, because each type adds instrumentation, slows queries and costs more. Teams must decide in advance what’s worth keeping, and discard the surrounding context.

“We were trying to use AI agents to answer business questions like ‘which of our users are on the same path as the ones who churned last month?’,” said Keewano Co-founder and CEO, Mark Kardashov. “You could see what happened on any dashboard, but why it happened lived somewhere the databases couldn’t reach. Our databases had been designed for humans querying tables, not machines that need to reason live, with complete context. To support agents properly, we realized we’d have to build a completely new storage format.”

KeewanoDB takes a fundamentally different architectural approach. KeewanoDB keeps each entity’s complete event sequence together and in order, so an agent can read answers directly from the raw data rather than reconstruct them, allowing for much faster and more accurate queries. With KeewanoDB, you can query a quarter of a billion events in under half a second, returning context-ready results agents can reason over immediately.

With KeewanoDB, an AI agent can investigate questions a dashboard can’t: why a customer churned, what sequence of behaviors led to an outcome, what distinguishes one group of users from another, or any new and complex behavioral questions no one thought to model in advance. An agent can see what happened before what, identify the patterns users have in common, and proactively surface emerging risks.

KeewanoDB doesn’t use per-event pricing, so organizations can capture more and query more. The fully managed Keewano Cloud service connects alongside an existing data warehouse or replaces it, using standard integrations. Organizations can plug-in their own AI agents or use Keewano’s.

Keewano was co-founded in 2024 by Mark Kardashov, Dima Karger, Pavel Bibergal and Vitaly Bukhovsky – a team with two prior exits and a decade running analytics at gaming scale. Kardashov and Bukhovsky have built and sold two companies together: TestProject acquired by Tricentis in 2019, and Devalore acquired by Abra in 2022. Bibergal was CTO at Plarium and Karger led one of its largest studios, building and scaling games for millions of players globally.

“Every wave of AI adoption exposes the layer underneath it that wasn’t built for the new workload,” said Judah Taub, Managing Partner at Hetz Ventures. “We think machine reasoning is exposing exactly that gap in analytics infrastructure, and Keewano is addressing it directly rather than patching around it. That’s why we led the round.”

“In 1964, Japan didn’t try to make trains faster on the same track. They built a new line,” said Kardashov. “Databases are at that fork now. AI agents need a fundamentally different data architecture, and we’ve built KeewanoDB as the new line.”

About Keewano

Keewano is the first database for machine reasoning at scale. Traditional analytics databases are optimized for humans asking known questions through tables, dashboards and predefined views. AI agents ask differently, so KeewanoDB’s storage format was designed around how machines reason: every event complete, in order, in context, and live the moment it lands. That design unlocks unlimited events, agent-scale throughput, and the grounded context agents need behind every answer. With KeewanoDB, organizations can retain more data, query large event histories quickly, and reduce the storage and processing overhead of agentic analysis. KeewanoDB is also the only database of its kind that does not charge per event – a model made possible by an engine built specifically for machines. Founded by a team with deep experience across gaming, B2B SaaS and infrastructure, Keewano is backed by Hetz Ventures, a16z speedrun, Remagine Ventures and DIG Ventures. Learn more at https://keewano.com/.

Media Contact
[email protected]

Photo: https://mma.prnewswire.com/media/3009000/Keewano_founders.jpg

SOURCE Keewano

John Duffin transitions to Chief Strategy and Corporate Development Officer as 3 Boomerang Capital portfolio company continues to expand its capabilities and scale

FISHERS, Ind., Sept. 15, 2026 — Pinnaql, a 3 Boomerang Capital portfolio company and professional services provider delivering consulting and subject matter expertise to pharmaceutical, biotech and medical device organizations, today announced the appointment of Allison Kerska as Chief Executive Officer, effective immediately. John Duffin, who has led Pinnaql through a period of significant growth and transformation, will transition to Chief Strategy and Corporate Development Officer.

The leadership evolution comes at a pivotal point in Pinnaql’s evolution. In less than two years, the company has brought multiple businesses together into an integrated life sciences consulting platform, expanded its geographic presence and broadened its capabilities across engineering, automation, laboratory operations, quality systems, project and program management, CQV/CSV, data integrity and regulatory compliance.

Ms. Kerska brings extensive experience leading and scaling professional services organizations. Most recently, she served as President of ELIQUENT Life Sciences, where she led a GxP consulting and advisory business supporting clients across complex regulatory, quality and operational matters. Previously, she spent more than 15 years in workforce and talent solutions, including senior leadership roles at KellyOCG.

“Pinnaql has reached an exciting inflection point,” said Allison Kerska, Chief Executive Officer of Pinnaql. “John and the team have built an exceptional foundation, bringing together talented people and complementary capabilities around a clear vision for serving life sciences clients. The opportunity now is to scale that platform thoughtfully without losing what makes Pinnaql differentiated: deep expertise, trusted relationships and an ability to make complex challenges easier for our clients.”

Pinnaql’s growth strategy is centered on creating an increasingly comprehensive resource for life sciences organizations. By bringing specialized expertise together within Pinnaql, clients can access engineering, scientific, quality, compliance and digital capabilities through a single trusted partner.

“We have built the foundation, brought together outstanding teams and created a platform with tremendous potential,” said John Duffin, Chief Strategy and Corporate Development Officer of Pinnaql. “Allison has the experience to take what we have built and scale it with the operational discipline this next chapter requires. My new role allows me to remain deeply involved in building and steering Pinnaql’s future, particularly through acquisitions, integration, digital validation and AI.”

The appointment represents the next phase of 3 Boomerang Capital‘s strategy to build Pinnaql into a differentiated and scalable life sciences services platform.

“Pinnaql has made significant progress building an integrated platform in an attractive and resilient segment of the life sciences market,” said Peter Wen, Principal at 3 Boomerang Capital. “Allison brings the operating leadership and professional services experience to drive disciplined growth and realize the value of the capabilities we have unified, while John’s continued focus on M&A and strategic innovation drives the momentum behind the platform. We believe this leadership structure positions Pinnaql well for its next chapter of growth and value creation.”

Under Ms. Kerska’s leadership, Pinnaql will continue advancing its strategy of combining deep technical expertise with a scalable, integrated operating model to support increasingly complex development, commercialization and manufacturing needs across the life sciences sector.

About Pinnaql

Pinnaql is a 3 Boomerang Capital portfolio company and professional services provider delivering consulting and subject matter expertise to pharmaceutical, biotech and medical device organizations. Pinnaql provides integrated expertise across engineering and automation, laboratory operations, quality systems, project and program management, data integrity, commissioning, qualification and validation (CQV), computer system validation (CSV), audit readiness, remediation support and regulatory compliance.

By bringing specialized expertise together, the company helps life sciences organizations navigate complexity, accelerate programs and maintain compliance across the product lifecycle. For more information, please visit https://www.pinnaql.com/.

About 3 Boomerang Capital

3 Boomerang Capital, L.P. is a lower-middle-market healthcare private equity firm committed to fostering creative investment partnerships with healthcare entrepreneurs across North America and Western Europe. 3BC’s areas of investment focus span four key healthcare sectors: biopharma outsourcing, medical device and diagnostic manufacturing, information technology and tech-enabled services, and alternate site care.

The firm specializes in backing founder-led businesses, providing the guidance and resources needed for successful growth and innovation in the healthcare market. By strategically concentrating on four core areas, 3 Boomerang Capital is well-equipped to deliver on its mission of empowering healthcare entrepreneurs and propelling healthcare businesses to new heights. The firm is currently investing out of its flagship fund, 3 Boomerang Capital I, LP, a $376 million investment vehicle. To learn more, please visit https://www.3boomerang.com/.

SOURCE Pinnaql

Former Tulsa Innovation Labs Managing Director brings more than a decade of experience in entrepreneurship, economic development and ecosystem building to lead Rev1’s next chapter

COLUMBUS, Ohio, Sept. 15, 2026 — Rev1 Ventures, the Midwest venture studio that partners with innovators in SaaS/AI, deep tech and life sciences, today announced that Jennifer Hankins has been named its new Chief Executive Officer and President following a national search for a leader to build on Rev1’s track record of supporting entrepreneurs, strengthening the innovation ecosystem and driving economic impact across Ohio.

Hankins joins Rev1 from Tulsa Innovation Labs, where she served as Managing Director and led the organization’s strategy, partnerships and portfolio of initiatives focused on strengthening Tulsa’s innovation economy. There, she helped lead one of only two U.S. regions to win both EDA Build Back Better Regional Challenge and Tech Hubs Implementation Funding.

She brings more than a decade of experience across entrepreneurship and economic development, working with founders, businesses, investors and community partners to build stronger regional economies.

“Rev1 has played an important role in putting Columbus on the map as a place where entrepreneurs can build and scale,” said Hankins. “We have an opportunity to build on that momentum and think even bigger about what’s possible — connecting more founders, investors, companies and institutions to strengthen the ecosystem and create more opportunities for entrepreneurs to succeed. I’m eager to join the Rev1 team to help take that work even further across Central Ohio and beyond.”

Before joining Tulsa Innovation Labs, Hankins served as Vice President of Entrepreneurship and Small Business at the Tulsa Regional Chamber, where she helped grow the regional entrepreneurial ecosystem and managed the Chamber’s business incubator for high-growth startups. She also served as Manager of Business Retention and Expansion on the Greater Oklahoma City Chamber of Commerce’s Economic Development team. Earlier in her career, she worked in the Kansas City region for the Wyandotte Economic Development Council.

“Jennifer brings a rare combination of entrepreneurial ecosystem experience, economic development expertise and collaborative leadership,” said Sue Zazon, Rev1 Board Chair and President of Huntington Bank’s Central Ohio Region. “She understands how to bring founders, investors, businesses and community leaders together around shared opportunities that can strengthen an entire region. Her experience and vision will ensure Rev1 builds on its momentum so it can continue serving entrepreneurs and supporting innovation.”

Rev1 was recently named to TIME’s inaugural America’s Best Incubators & Accelerators 2026 list, ranking as the highest Ohio-based organization included. Since launching, Rev1 has supported more than 1,700 startups, funded more than 200 unique companies and helped generate more than $7.7 billion in economic impact statewide. Rev1 recently expanded its presence in downtown Columbus with Rev1 at The Peninsula, a founder-focused innovation hub designed to help software and advanced technology startups grow faster and more effectively.

“Jennifer brings the vision, energy and conviction Rev1 needs for what comes next,” said Tom Walker, executive chairman of the Rev1 Ventures Board. “She understands that building a thriving innovation economy takes more than great ideas – it takes the right people, resources and opportunities coming together to turn those ideas into high-growth companies. I’m confident Jennifer will challenge us to think bigger, move with purpose and take Rev1’s impact to the next level.”

Rev1’s work is made possible through the continued support of the State of Ohio’s Third Frontier program and its dedicated funding and corporate partners.

About Rev1 Ventures
Rev1 Ventures is where founders go to build. As a Midwest venture studio, Rev1 partners with innovators in Saas/AI, deep tech, and life sciences to turn bold ideas into scalable companies. From day one, Rev1 helps startups move faster and grow smarter by validating markets, gaining traction, and becoming venture ready. A catalyst for early-stage growth, Rev1 connects founders to the mentors, partners, and early customers that accelerate progress and position startups to attract investors. With hands-on support, a powerful network, and collaborative spaces designed for growth, Rev1 gives startups the foundation to build stronger and scale. For more information, visit https://www.rev1ventures.com.

SOURCE Rev1 Ventures

New term debt facility marks Generate’s first community solar financing with MUFG and builds on $1.4 billion
of financing commitments in the first half of 2026

SAN FRANCISCO, Sept. 15, 2026 — Generate Capital (“Generate”), a leading investor, owner and operator of critical infrastructure, today announced the closing of a $117 million term debt facility with MUFG to finance a portfolio of community solar projects. The transaction marks Generate’s first community solar financing with MUFG and further expands the company’s network of leading institutional financing partners.

The facility supports Generate’s Community Solar Fund 11, comprising 18 projects / 114MWdc across Illinois and New York. The financing will support Generate’s continued investment in community solar infrastructure that expands access to reliable and affordable power for communities and businesses.

“The closing of this facility with MUFG further expands our financing partner network and provides additional capital to support the continued growth of our community solar platform,” said Ed Bossange, Chief Capital Formation Officer at Generate Capital. “Combined with the significant financing activity we completed during the first half of the year, this transaction reflects the strength of our platform and our ability to attract capital from leading institutions across a diverse range of infrastructure solutions.”

“We are pleased to partner with Generate on this financing and support the continued growth of its community solar platform,” said Fred Zelaya, Managing Director at MUFG. “Generate has built a strong track record of developing and operating high-quality distributed energy assets, and this transaction reflects our shared commitment to financing critical infrastructure that delivers reliable, affordable power to communities across the country.”

The transaction builds on significant capital formation momentum for Generate in 2026. During the first half of the year, the company closed approximately $1.4 billion of financing commitments across a diversified portfolio of infrastructure investments spanning community solar, battery energy storage systems and energy efficiency.

First-half highlights included:

• The closing of a 104 MW community solar portfolio alongside Monarch Private Capital, supporting more than 15 community solar projects expected to deliver approximately $200 million in investment tax credits.
• A $61 million senior secured U.S. Private Placement to finance energy efficiency projects for a leading investment-grade industrial customer. The 15-year construction-to-term financing represents Generate’s inaugural 4(a)2 U.S. Private Placement, further diversifying the firm’s funding sources and financing partner base.

Generate’s recent financing activity reflects continued institutional demand for high-quality infrastructure assets with long-term contracted cash flows, as well as the company’s ability to structure financing solutions across multiple infrastructure sectors.

About Generate Capital

Generate Capital is an investor and operator providing reliable and affordable energy solutions to customers for over a decade. Founded in 2014, Generate focuses on accelerating the energy transition by helping large energy users access power and connection faster in a grid constrained world. The firm supports data centers and other power-intensive facilities with multi-technology scalable energy infrastructure solutions, combining deep investment expertise with hands-on operating capabilities. Since inception, Generate has raised more than $16 bn in capital and built a proven track record across critical infrastructure assets. 

About MUFG and MUFG Americas

Mitsubishi UFJ Financial Group, Inc. (MUFG) is one of the world’s leading financial groups with over 360 years of history. Headquartered in Tokyo, MUFG has a global network with approximately 2,000 locations in more than 40 countries. MUFG’s Americas operations, including its offices in the U.S., Latin America, and Canada, are primarily organized under MUFG Bank, Ltd. and subsidiaries, and are focused on Global Corporate and Investment Banking, Japanese Corporate Banking, and Global Markets. For locations, banking capabilities and services, career opportunities, and more, visit https://www.mufgamericas.com/.

SOURCE Generate Capital